new pfizer ceo appoint like signal continu
page full analyst note oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim aug
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
foundat remain solid base strong cash flow
gener basket divers drug compani larg size
confer signific competit advantag develop new
drug unmatch heft combin broad portfolio
patent-protect drug help build wide econom
moat around busi
size establish one largest economi scale
pharmaceut industri busi drug develop
need lot shot goal success financi
resourc establish research power support
develop new drug also mani year
struggl bring import new drug launch
sever potenti blockbust cancer heart diseas
commit postapprov studi provid
salespeopl armamentarium data market
campaign lead salesforc emerg
countri posit compani benefit dramat
increas wealth nation brazil russia india china
turkey
entrench industri leader face challeng
near term loss patent protect sever drug
weigh futur growth particular recent patent loss
viagra eventu patent loss lyrica
slow long-term growth
howev believ oper withstand
upcom gener competit acquisit wyeth
help insul one particular patent loss follow
merger much stronger posit vaccin
industri pneumococc vaccin prevnar vaccin tend
resist gener competit
manufactur complex rel lower price
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one world largest pharmaceut firm annual sale
billion also spend lead amount research
develop close billion annual histor sold mani
type healthcar product chemic prescript drug
vaccin account major sale top seller includ pneumococc
cardiovascular treatment eliqui immunolog drug enbrel xeljanz
sell product global intern sale repres
close total sale within intern sale emerg market
major contributor repres fifth total compani sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
overal strategi oct
follow announc name albert bourla
new ceo effect jan expect
chang fair valu estim wide moat rate
continu view stock modestli under-valued
pipelin like fulli appreci
announc bourla move top spot signal
like continu strateg focu move
toward area unmet medic need drug develop
divest asset area lack scale make
synergist mid-size acquisit guid
continu steadi growth bourla background
chief oper offic well leadership
innov drug busi give strong credenti
run overal organ believ gain
spot januari larg set eventu ceo
appoint thought telegraph passag
leadership welcom pathway contrast past
ceo chang ian read abruptli took
follow increas concern previou ceo
bourla probabl want leav mark
legaci expect calm hand helm similar read
decis made calcul way best interest
sharehold patient
increas fair valu estim per share
basi higher project rare-diseas
drug tafamidi look increasingli well posit
breakthrough statu grant
cardiomyopathi diseas associ progress
heart failur phase data drug drive
approv lead billion annual peak sale
look core busi expect annual
sale growth next three year
acquisit new drug off-set gener competit
howev bottom line project slightli healthier
annual growth rate next three year
cost-cut plan share buyback take shape
model unannounc acquisit acquisit hold
potenti acceler compani growth rate
long term believ diversifi line-up drug
reduc volatil earn anticip
restructur effort elimin duplic
posit help allevi margin pressur
high-margin product lose exclus cost capit
perspect estim cost equiti
weight averag cost capit line peer
larg base low volatil cash flow
divers product portfolio inelast demand rate
uncertainti low scenario analysi assum
base-cas fair valu estim bull-cas fair
valu estim probabl bear case
probabl project fair valu rel
base case scenario analysi show minor varianc
henc low uncertainti rate key factor affect
scenario analysi includ degre success
brand drug pipelin along magnitud market
pressur current market drug within group
recent launch drug import driver
valuat ibranc cancer addit unknown
magnitud biosimilar competit
immunolog diseas weigh certainti
enbrel
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ face stabl moat trend next
five year compani major patent loss repres
total sale howev strong pipelin
combin stabl current market drug lead
modest growth annual period
exclud acquisit also patent exposur
face biolog shouldnt declin fast
small molecul patent expir offset
patent loss pipelin side expect
billion peak annual sale three new drug includ
recent launch ibranc cancer pipelin drug
tanezumab pain ertugliflozin diabet
turn macroeconom environ
sever headwind make solid strateg move
address challeng neg side
risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
organ pharmaci benefit manag
consolid past decad use
grow size demand lower drug price reduc
coverag less innov drug forc drug firm
push true innov reduc power pfizer
distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov face sever headwind
pipelin focus innov treatment area
unmet medic area cancer payer
coverag price power remain strong outsid
pipelin compani strong entrench vaccin
consum healthcar give firm relief
pressur drug group
develop next gener drug gener
competit aris addit hold
diversifi product portfolio
product
concentr compani largest product prevnar
repres total sale howev
expect typic gener competit vaccin due
complex manufactur rel low price
product expect new product mitig
eventu gener competit key drug also
pfizer oper structur allow cost-cut follow
patent loss reduc margin pressur lost
line creat enorm cash flow need fund
averag million develop cost per new drug
addit compani power distribut network
set compani strong partner smaller drug
compani lack resourc entrench
consum vaccin franchis creat ad layer
competit advantag stem brand power
consum healthcar manufactur cost advantag
vaccin divis consid sell
consum healthcar group potenti divest
materi impact compani moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin product improv sever
potenti game-chang immunolog
major
blockbust breast cancer
ibranc develop
oth stock support dividend yield
expect steadi cash flow support dividend
owhil decid break compani
innov core establish drug group
increas visibl segment option
revisit decis creat potenti futur valu
research
late-stag pipelin look strong enough
drive robust growth
oalthough compani worst
patent cliff still face recent major patent loss
viagra futur one lyrica
osever late-stag pipelin drug
enter crowd market may limit share gain
due delay entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
hold strong financi posit larg
degre flexibl end debt/capit
stood debt/ebitda ratio
suggest remain solid financi foot
major cash flow deriv divers portfolio
product dont expect high degre volatil
futur earn like continu make
acquisit believ rel easili take debt
fund larger deal
face gener competit increasingli stringent
fda stronger managed-car pharmaci benefit
manag negoti power new drug develop
becom challeng sever diseas area
pharmaci benefit manag grown past
two decad power entiti negoti lower
drug price although remot litig risk remain
evidenc merck high settlement cost involv
vioxx also sever pipelin drug reach
market behind competitor may increas risk
commerci failur put downward price
pressur drug clinic data lack posit
differenti brand competit front merck
work develop next-gener pneumococc
vaccin cover valent could threaten
prevnar cover two fewer valent howev
overal view uncertainti low base
low volatil cash flow divers product portfolio
inelast demand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
govern pension fund norway global
share
fund
share
fund
rate stewardship standard
compani made mani poor capital-alloc decis
past decad current manag team
appear focus significantli better use cash
includ share buyback dividend also decis
sell nutrit anim healthcar busi
appear creat valu sharehold
front acquisit hospira strengthen
moat establish drug segment price look
reason howev high price paid mediv
fail attempt acquir astrazeneca allergan
concern
surpris move name longtim veteran
ian read ceo post abruptli replac jeffrey kindler
believ earlier-than-anticip departur kindler
larg due person reason believ
transit rais red flag read bring
year experi post
recent charg compani biopharmaceut
busi ceo read brought stamp post
signal strong willing cut buy back
share believ read leadership bring chang
need increas compani growth potenti
report side account transpar ideal larg
financi distort caus frequent
acquisit reconcili gener accept
account practic result adjust result
complex dilut clariti earn statement
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
still strong posit analyz key point
around moat larg pharmaceut industri
post strong rare-diseas drug data lead
report posit phase data rare-diseas drug
tafamidi transthyretin amyloid cardiomyopathi attr-
cm lead increas annual peak tafamidi
project billion million also
increas fair valu estim per share
continu believ under-valued view
strong tafamidi result good exampl
matur pipelin strengthen futur cash flow
reinforc compani wide moat
peak tafamidi sale project base strong
efficaci limit treatment option like strong price
power phase data show reduct all-
caus mortal drive strong util
drug favor reimburs preval
diseas limit estim
peopl develop market
accord believ less diagnosi
rate show like difficulti reach patient
howev without approv drug patient
popul histor believ
motiv diagnos diseas also limit
patient size combin strong efficaci enabl
strong price least annual even
account value-bas price rare-diseas
drug util overal project chanc
approv base strong efficaci benign side effect
profil long term expect diagnosi
rate improv tafamidi use third
patient
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
drug option avail attr-cm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
alnylam onpattro approv anoth relat rare
diseas polyneuropathi hereditari attr strong
efficaci onpattro
all-caus
hospit mortal may drive off-label
usag drug directli tafamidi expect
off-label competit limit
complet overview pipelin pleas see
threat secur pharma moat
post strong buoy eliqui xeljanz
ibranc lead fve increas jul
post strong second-quart result ahead
consensu expect plan slightli
rais fair valu estim base result
continu view stock under-valued market
like underappreci firm emerg pipelin
strength pipelin current market drug also
help reinforc wide-moat rate
quarter strong gain sever establish drug
eliqui cardiovascular diseas xeljanz rheumatoid
arthriti ibranc breast cancer help off-set gener
competit older drug lead total sale growth
oper expect growth acceler
expect gener competit neurosci
drug lyrica total sale slow growth
nevertheless eliqui continu gain share
older drug treatment warfarin base significantli better
efficaci side effect also new indic ulcer
coliti psoriat arthriti xeljanz drive futur
growth ibranc recent launch intern set
strong growth potenti expect posit adjuv
studi reacceler growth unit state
howev ibranc studi fail improv
overal surviv os even though studi
optim show os benefit competit data
far look similar ibranc competitor could use
setback studi show os benefit
beyond current market drug develop
good pipelin decis move next-gener
pneumococc vaccin cover serotyp
prevnar merck late-stag competit
threat phase develop keep vaccin
franchis well-posit mani year also
posit phase data pain drug tanezumab open
potenti high-risk/high-reward opportun
model probabl success drug
complet review ngf market outlook
tanezumab pleas see report pain potenti
lot lilli regeneron also report
lilli regeneron address unmet need chronic pain
market provid insight thoma schnitzer md phd
outlook ngf class
lilli strong tanezumab data
report posit top-lin phase data
pipelin pain drug tanezumab rel clean side
effect profil support above-consensu
expect drug under-valued call
stock project tanezumab sale billion
ahead consensu estim close million
side effect plagu tanezumab nerv
growth factor class past believ current
clinic studi better manag side effect
overal strong clinic data help reinforc
phase studi treat osteoarthr pain
sign osteonecrosi less rate rapidli
progress osteoarthr believ support
chanc approv drug
treat
osteoarthr pain howev detail around sever
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
level side effect disclos like
come later year find lack osteonecrosi
break bone tissu encourag side
effect major reason clinic hold class
drug close six year ago efficaci side
primari
endpoint consist histor studi
expect sever phase studi treat pain relat
osteoarthr lower back cancer read
next month probabl approv
treat osteoarthr pain probabl
approv treat lower back pain project annual peak
sale billion
complet review ngf market outlook
tanezumab pleas see report pain potenti
lot lilli regeneron also report
lilli regeneron address unmet need chronic pain
market provid insight thoma schnitzer md phd
outlook ngf class
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
polit driven difficult implement
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
gener pressur manufactur order time
weigh share look under-valued
report first-quart result slightli
consensu top-lin expect dont expect
major chang fair valu estim
continu view stock under-valued partli due
underappreci overal growth potenti
grow strength oncolog led ibranc continu
view compani wide moat support one
widest portfolio patent protect drug
competit expect lead close billion
lost sale next five year quarter gener
pressur neurosci drug lyrica immunolog drug
enbrel erectil dysfunct drug viagra weigh
result like continu creat drag
howev expect new pipelin drug recent
launch drug off-set gener headwind lead total
overal sale growth annual next three
year bottom line grow faster due minor
oper margin expans lower tax rate share
repurchas complet review portfolio
current market drug pipelin drug pleas see
threat secur pharma moat
quarter total sale fell oper order
time gener competit manufactur issu
older inject drug weigh growth expect
growth acceler subsequ quarter destock
hurt cancer drug ibranc immunolog drug xeljanz
expect trend revers later year
despit emerg competit fast-grow drug
pfizer first-mov advantag combin rel
well-posit efficaci side effect profil
result continu growth drug expect
ibranc gener peak sale billion base
expand indic includ adjuv use addit
 order time prevnar led sale declin
quarter expect continu strength intern
older patient popul stabil
order return vaccin growth also
pfizer next-gener vaccin cover valent
move phase develop
provid protect merck late-stag competit
vaccin target valent
patent loss continu work gener
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
